Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma

Alyx B Porter Umphrey, Dirk M. Bernold, Caterina Giannini, Robert L. Foote, Michael J. Link, Kerry D. Olsen, Timothy J. Moynihan, Jan Craig Buckner

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Esthesioneuroblastoma (ENB) is a rare tumor arising from the olfactory epithelium in the upper nasal cavity. Prior reviews have found efficacy of chemotherapy for high grade tumors in the advanced setting. However, little information is available regarding chemotherapy in the adjuvant setting. Methods: A retrospective review of 76 patients treated at the Mayo Clinic for esthesioneuroblastoma from 1976 to 2003 was performed to evaluate adjuvant chemotherapy (AC) in these patients. Pathology slides were reviewed to assign Hyam's grade, and modified Kadish staging was available for all patients used in the analysis. Results: Twelve patients were identified to have had full surgical resection of Stage C, high grade (grade 3 or 4) tumors. Six of these patients received AC, and six did not. Most AC was cisplatin and etoposide based. Median time to relapse for patients who did and did not receive AC is 35 and 10.5 months respectively. The median overall survival (OS) for patients that received AC was 83+ (range 21-119+ months). The median OS for patients not receiving AC is 78 months (range 9-240+ months). Conclusions: This small retrospective series suggests that adjuvant therapy for patients with high grade, Stage C esthesioneuroblastoma is of benefit following complete resection. Radiation therapy alone provides an improvement in time to relapse, which may be increased further with the addition of cisplatin and etoposide based chemotherapy.

Original languageEnglish (US)
Pages (from-to)201-204
Number of pages4
JournalJournal of Neuro-Oncology
Volume90
Issue number2
DOIs
StatePublished - 2008

Fingerprint

Olfactory Esthesioneuroblastoma
Adjuvant Chemotherapy
Etoposide
Cisplatin
Recurrence
Drug Therapy
Olfactory Mucosa
Neoplasms
Survival
Nasal Cavity
Radiotherapy
Pathology

Keywords

  • Adjuvant chemotherapy
  • Esthesioneuroblastoma
  • Radiation

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. / Porter Umphrey, Alyx B; Bernold, Dirk M.; Giannini, Caterina; Foote, Robert L.; Link, Michael J.; Olsen, Kerry D.; Moynihan, Timothy J.; Buckner, Jan Craig.

In: Journal of Neuro-Oncology, Vol. 90, No. 2, 2008, p. 201-204.

Research output: Contribution to journalArticle

Porter Umphrey, Alyx B ; Bernold, Dirk M. ; Giannini, Caterina ; Foote, Robert L. ; Link, Michael J. ; Olsen, Kerry D. ; Moynihan, Timothy J. ; Buckner, Jan Craig. / Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. In: Journal of Neuro-Oncology. 2008 ; Vol. 90, No. 2. pp. 201-204.
@article{ded433970f2643e7b47b4d0cb2f777b9,
title = "Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma",
abstract = "Background: Esthesioneuroblastoma (ENB) is a rare tumor arising from the olfactory epithelium in the upper nasal cavity. Prior reviews have found efficacy of chemotherapy for high grade tumors in the advanced setting. However, little information is available regarding chemotherapy in the adjuvant setting. Methods: A retrospective review of 76 patients treated at the Mayo Clinic for esthesioneuroblastoma from 1976 to 2003 was performed to evaluate adjuvant chemotherapy (AC) in these patients. Pathology slides were reviewed to assign Hyam's grade, and modified Kadish staging was available for all patients used in the analysis. Results: Twelve patients were identified to have had full surgical resection of Stage C, high grade (grade 3 or 4) tumors. Six of these patients received AC, and six did not. Most AC was cisplatin and etoposide based. Median time to relapse for patients who did and did not receive AC is 35 and 10.5 months respectively. The median overall survival (OS) for patients that received AC was 83+ (range 21-119+ months). The median OS for patients not receiving AC is 78 months (range 9-240+ months). Conclusions: This small retrospective series suggests that adjuvant therapy for patients with high grade, Stage C esthesioneuroblastoma is of benefit following complete resection. Radiation therapy alone provides an improvement in time to relapse, which may be increased further with the addition of cisplatin and etoposide based chemotherapy.",
keywords = "Adjuvant chemotherapy, Esthesioneuroblastoma, Radiation",
author = "{Porter Umphrey}, {Alyx B} and Bernold, {Dirk M.} and Caterina Giannini and Foote, {Robert L.} and Link, {Michael J.} and Olsen, {Kerry D.} and Moynihan, {Timothy J.} and Buckner, {Jan Craig}",
year = "2008",
doi = "10.1007/s11060-008-9645-y",
language = "English (US)",
volume = "90",
pages = "201--204",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma

AU - Porter Umphrey, Alyx B

AU - Bernold, Dirk M.

AU - Giannini, Caterina

AU - Foote, Robert L.

AU - Link, Michael J.

AU - Olsen, Kerry D.

AU - Moynihan, Timothy J.

AU - Buckner, Jan Craig

PY - 2008

Y1 - 2008

N2 - Background: Esthesioneuroblastoma (ENB) is a rare tumor arising from the olfactory epithelium in the upper nasal cavity. Prior reviews have found efficacy of chemotherapy for high grade tumors in the advanced setting. However, little information is available regarding chemotherapy in the adjuvant setting. Methods: A retrospective review of 76 patients treated at the Mayo Clinic for esthesioneuroblastoma from 1976 to 2003 was performed to evaluate adjuvant chemotherapy (AC) in these patients. Pathology slides were reviewed to assign Hyam's grade, and modified Kadish staging was available for all patients used in the analysis. Results: Twelve patients were identified to have had full surgical resection of Stage C, high grade (grade 3 or 4) tumors. Six of these patients received AC, and six did not. Most AC was cisplatin and etoposide based. Median time to relapse for patients who did and did not receive AC is 35 and 10.5 months respectively. The median overall survival (OS) for patients that received AC was 83+ (range 21-119+ months). The median OS for patients not receiving AC is 78 months (range 9-240+ months). Conclusions: This small retrospective series suggests that adjuvant therapy for patients with high grade, Stage C esthesioneuroblastoma is of benefit following complete resection. Radiation therapy alone provides an improvement in time to relapse, which may be increased further with the addition of cisplatin and etoposide based chemotherapy.

AB - Background: Esthesioneuroblastoma (ENB) is a rare tumor arising from the olfactory epithelium in the upper nasal cavity. Prior reviews have found efficacy of chemotherapy for high grade tumors in the advanced setting. However, little information is available regarding chemotherapy in the adjuvant setting. Methods: A retrospective review of 76 patients treated at the Mayo Clinic for esthesioneuroblastoma from 1976 to 2003 was performed to evaluate adjuvant chemotherapy (AC) in these patients. Pathology slides were reviewed to assign Hyam's grade, and modified Kadish staging was available for all patients used in the analysis. Results: Twelve patients were identified to have had full surgical resection of Stage C, high grade (grade 3 or 4) tumors. Six of these patients received AC, and six did not. Most AC was cisplatin and etoposide based. Median time to relapse for patients who did and did not receive AC is 35 and 10.5 months respectively. The median overall survival (OS) for patients that received AC was 83+ (range 21-119+ months). The median OS for patients not receiving AC is 78 months (range 9-240+ months). Conclusions: This small retrospective series suggests that adjuvant therapy for patients with high grade, Stage C esthesioneuroblastoma is of benefit following complete resection. Radiation therapy alone provides an improvement in time to relapse, which may be increased further with the addition of cisplatin and etoposide based chemotherapy.

KW - Adjuvant chemotherapy

KW - Esthesioneuroblastoma

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=53349141235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53349141235&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9645-y

DO - 10.1007/s11060-008-9645-y

M3 - Article

C2 - 18633576

AN - SCOPUS:53349141235

VL - 90

SP - 201

EP - 204

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -